Wall Street Bulls are Pounding the Table Over Amazon, Eli Lilly, and Apple

Core Insights - Major indices are attempting to rebound after a recent pullback, with optimism surrounding potential Federal Reserve interest rate cuts and a resurgence in tech stocks [3][5] Company Summaries Amazon - Wells Fargo raised its price target on Amazon to $295 per share, maintaining an overweight rating. The firm anticipates that sustained supply constraints in the cloud industry could lead to a doubling of AWS capacity by 2027, potentially adding $150 billion in annual revenue, which would significantly enhance revenue estimates for 2027 and 2028 [5][6] Eli Lilly - Bank of America reiterated a buy rating on Eli Lilly, increasing its price target from $950 to $1,286. The firm highlights Eli Lilly's leadership in the obesity and diabetes market with its GLP-1 franchise, Zepbound/Mounjaro, and expects the launch of a new oral obesity medication in early 2026 [7][8] Apple - Bernstein reiterated an outperform rating on Apple, noting strong iPhone sales. In October, Apple achieved a record single-month market share of 24.2%, with unit sales increasing by 30% month-over-month and 12% year-over-year, driven by robust sales in both China and the US [9]